
May 31 (Reuters) - Merck MRK.N:
KEYTRUDA® (PEMBROLIZUMAB) PLUS TRODELVY® (SACITUZUMAB GOVITECAN-HZIY) REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 35% VERSUS KEYTRUDA PLUS CHEMOTHERAPY IN FIRST-LINE PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)
MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 11.2 MONTHS MEDIAN PFS VERSUS 7.8 MONTHS WITH CHEMOTHERAPY
MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 35% REDUCTION IN RISK OF DISEASE PROGRESSION OR DEATH
MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 59.7% ORR VERSUS 53.2% WITH CHEMOTHERAPY
MERCK & CO INC - KEYTRUDA PLUS TRODELVY SHOWS 16.5 MONTHS DOR VERSUS 9.2 MONTHS WITH CHEMOTHERAPY